Kevin Han
CFO @ Biological Dynamics
San Diego, United States
Kevin Han is a seed investor at Biological Dynamics in San Diego focused on FinTech and Cryptocurrency. Currently, Kevin is CFO of Biological Dynamics, a biotech company, based out of San Diego, CA, where he leads financial operations and efforts for general IPO Readiness and oversees the company’s strategy and long-term planning initiatives. Prior, Kevin led investor relations, corporate communications, and corporate sustainability strategies atBio-Rad Laboratories. During his tenure, he developed and implemented a comprehensive investor relations program and served as a strategic thought partner on corporate strategy, business development, forecasting, and long-term planning. Prior to Bio-Rad, Kevin was a Portfolio Manager for various asset management firms, including Lombard Odier, BlueCrest and Visium, having led diligence on numerous IPOs and equity financing transactions. Kevin started his career at Morgan Stanley, and later Goldman Sachs, where he covered the medical technology and diagnostics sectors, and contributed to teams named #1 and Best Up & Comer by Institutional Investor. Kevin holds a BS in Business Administration from UNC Kenan-Flagler Business School, was pre-med at the University of North Carolina at Chapel Hill, and has completed executive education business leadership programs at London Business School and Harvard Business School.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 14%
Last updated:
For AI agents: llms.txt
Industries Kevin Han invests in
Stages Kevin Han invests in
Countries Kevin Han invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $4.7M–$8M
Investment Focus
Industry
- FinTech 3 (43%)
- Cryptocurrency 3 (43%)
- Software 2 (29%)
- Health Care 2 (29%)
- Trading Platform 2 (29%)
Stage
- Seed 3 (43%)
- Series C 1 (14%)
- Series E 1 (14%)
- Funding Round 1 (14%)
Country
- United States 4 (57%)
- Bahamas 1 (14%)
- Singapore 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Subtle Medical
|
Subtle Medical is a healthcare technology company that provides AI-powered medical imaging. Its products, SubtlePET and SubtleMR, are FDA Cleared and CE Marked AI product that enhances images in PET and MR exams aimed for faster & safer workflow.The company's SubtleGAD technology is also awarded by RSNA and a $1.6M NIH SBIR Grant tofacilitate the adoption using AI to make imaging exams safer. They provide a vendor-agnostic AI infrastructure powering its products and providing service and analytics to clinical imaging providers.Subtle Medical's goal is to improve the quality, value, and accessibility of medical imaging by significantly reducing cost, imaging time, and radiation dose. | $33M / Series C / Jun 02, 2026 | |
PowerTrade
|
Mobile crypto options and derivatives platform | $4.7M / Seed / Sep 17, 2020 | |
FTX
|
FTX Exchange is a cryptocurrency exchange company that develops a platform for professional trading firms. They strive to build a platform suitable for professional trading firms and intuitive enough for first-time users. FTX supports quarterly and perpetual futures for all cryptocurrencies, leveraged tokens, and OTC.FTX was incubated by AlamedaResearch, a top cryptocurrency liquidity provider. Because of this, FTX has had industry order books from day one. | $8M / Seed / Aug 06, 2019 | |
Indigo
|
Indigo is an agricultural technology company that focuses on improving the sustainability and productivity of agriculture. The company focuses on the microbes that have evolved in conjunction with plants over billions of years to optimize their health and maximize their productivity. Indigo believes we are at the forefront of something that servesthe needs of both farmers and consumers. For farmers, the yield benefits will help improve grower profitability while increasing our capacity to feed a growing population. For consumers, Indigo can begin to make fundamental changes in how our food is grown; like being more efficient with water, and reducing the use of nitrogen fertilizer and pesticides over time. | $250M / Series E / Sep 18, 2018 | |
Sentz Global
|
MobileCoin is a cryptocurrency platform that develops P2P payment tokens and digital payment systems for mobile. It combines privacy, security, and distributed trust with a great user experience. MobileCoin is designed so that a mobile messaging application like WhatsApp, Facebook Messenger, or Signal could integrate with a MobileCoin wallet. | $30M / Apr 24, 2018 | |
Avail Medsystems
|
Avail Medsystems is a medical technology company that develops software intended to digitize physical presence in operating rooms. The company specializes in designing and manufacturing medical devices that can be utilized during procedures for video conferencing with other medical professionals. It aims on democratizing access to clinical andprocedural expertise by removing physical, economic, and logistical barriers. Avail Medsystems' Procedural Telemedicine solution addresses these challenges by enabling on-the-go collaboration with any remote healthcare professional. The company was founded in 2018 and based in Palo Alto, California. | Seed / Jun 28, 2013 | |
|
Avail Medsystems
|
Avail Medsystems is a medical technology company that develops software intended to digitize physical presence in operating rooms. The company specializes in designing and manufacturing medical devices that can be utilized during procedures for video conferencing with other medical professionals. It aims on democratizing access to clinical andprocedural expertise by removing physical, economic, and logistical barriers. Avail Medsystems' Procedural Telemedicine solution addresses these challenges by enabling on-the-go collaboration with any remote healthcare professional. The company was founded in 2018 and based in Palo Alto, California. | Seed |
Co-Investors
About Biological Dynamics
Biological Dynamics, Inc. is a healthcare company committed to improving global health outcomes by detecting diseases in their earliest stages. The company's proprietary platform simplifies access to native-state biomarkers and nanoparticles, enabling multiomics applications. The company is focused on detecting cancers by applying its platformtechnology along with its machine learning capabilities. For more information, please visit www.biologicaldynamics.com and follow us at @BiodynSD on Twitter.It was founded in 2008 and is headquartered in San Diego, California.
Biological Dynamics Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Paul Billings
Chief Executive Officer & Director
|
|||
|
Kevin Han
CFO
|
|||
Peter Wulff
Chief Financial Officer
|
|||
Raj Krishnan
CEO
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Kevin Han invest in?
Kevin Han invests primarily in FinTech, Cryptocurrency and Software startups, most often at Seed and Series C stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Kevin Han's check size?
Kevin Han typically joins rounds of $4.7M–$8M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Kevin Han participates in.
How do I contact Kevin Han?
Public channels for Kevin Han include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Kevin Han last invest?
The most recent investment recorded for Kevin Han closed in Jun 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
